Kamada, Chiesi Farmaceutici Terminate Inhaled Alpha-1 Antitrypsin Therapy Deal Post author:Sam Post published:November 19, 2017 Post category:BioPharma Kamada now maintains full, worldwide commercial rights to its inhaled AAT. Source: BioSpace You Might Also Like <b>Clarivate Analytics</b> Launches New Product Suite, Reducing Risk And Saving Time For Researchers Selecting Next Drug Target March 14, 2017 MyoKardia Sees Positive Results in Mid-Stage Heart Trial March 8, 2018 Arcus Biosciences, Wuxi Biologics Hammer Out R&D Cancer Pact Worth $816 Million+ August 16, 2017
<b>Clarivate Analytics</b> Launches New Product Suite, Reducing Risk And Saving Time For Researchers Selecting Next Drug Target March 14, 2017
